3-Deazauridine enhances the antileukemic action of 5-aza-2′-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 110-118

  Raynal, Noël J M ^a   Momparler, Louise F ^a   Rivard, Georges E ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

3 Deazauridine; 5 Aza 2 deoxycytidine; Acute lymphoblastic leukemia; Deoxycytidine kinase; Drug resistance; Epigenetic therapy; Synergy

Indexed keywords

3 DEAZAURIDINE; 5 AZA 2' DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW EXAMINATION; CANCER RESISTANCE; CANCER SURVIVAL; CASE REPORT; CELL STRAIN HL 60; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LEUKEMIA L 1210; MALE; MOUSE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; SURVIVAL TIME;

3-DEAZAURIDINE; ANIMALS; AZACITIDINE; CELL LINE, TUMOR; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA L1210; MALE; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650175624     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.014     Document Type: Article

References (36)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Garcia-Manero G., Yang H., Kuang S.Q., O'Brien S., Thomas D., Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 2009, 46:24-32.
3. Agirre X., Vilas-Zornoza A., Jimenez-Velasco A., Martin-Subero J.I., Cordeu L., Garate L., et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009, 69:4443-4453.
4. Davidsson J., Lilljebjorn H., Andersson A., Veerla S., Heldrup J., Behrendtz M., et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet 2009, 18:4054-4065.
5. Dunwell T.L., Hesson L.B., Pavlova T., Zabarovska V., Kashuba V., Catchpoole D., et al. et al: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 2009, 4:185-193.
6. Martin-Subero J.I., Ammerpohl O., Bibikova M., Wickham-Garcia E., Agirre X., Alvarez S., et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009, 4:e6986.
7. Shen L., Toyota M., Kondo Y., Obata T., Daniel S., Pierce S., et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003, 101:4131-4136.
8. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Agirre X., Barrios M., Navarro G., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004, 104:2492-2498.
9. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 2005, 32:443-451.
10. Rivard G.E., Momparler R.L., Demers J., Benoit P., Raymond R., Lin K., et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 1981, 5:453-462.
11. Momparler R.L., Rivard G.E., Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985, 30:277-286.
12. Yanez L., Bermudez A., Richard C., Bureo E., Iriondo A. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 2009, 23:1342-1343.
13. Onetto N., Momparler R.L., Momparler L.F., Gyger M. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2′-deoxycytidine. Semin Oncol 1987, 14:231-237.
14. Momparler R.L. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 2005, 423:9-16.
15. McPartland R.P., Wang M.C., Bloch A., Weinfeld H. Cytidine 5′-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. Cancer Res 1974, 34:3107-3111.
16. Li Z.R., Campbell J., Rustum Y.M. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Cancer Treat Reports 1983, 67:547-554.
17. 6-tumor cells. Cancer Res 1979, 39:3822-3827.
18. Brockman R., Shaddix S.C., Williams M., Nelson J.A., Rose L.M., Schabel F.M., et al. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine. Ann NY Acad Sci 1975, 8:501-521.
19. Momparler R.L., Momparler L.F. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2′-deoxycytidine and 3-deazauridine. Cancer Chemother Pharmacol 1989, 25:51-54.
20. Barlogie B., Plunkett W., Raber M., Latreille J., Keating M., McCredie K. In vivo cellular kinetic and pharmacological studies of 1-beta-d-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 1981, 41:1227-1235.
21. Stewart D.J., McCredie K.D., Barlogie B., Valdivieso M., Benjamin R.S., Burgess M.A., et al. Phase I study of 3-deazauridine in the treatment of adults with solid tumors. Cancer Treat Reports 1980, 64:1295-1299.
22. Moriconi W., Slavik M., Taylor S. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs 1986, 4:67-84.
23. Momparler R., Bouffard D.Y., Momparler L.F., Marquet J., Zittoun J., Marie J.P., et al. Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine. Int J Cancer 1991, 49:573-576.
24. Mills-Yamamoto C., Lauzon G.J., Paterson A.R. Toxicity of combinations of arabinosylcytosine and 3-deazauridine toward neoplastic cells in culture. Biochem Pharmacol 1978, 27:181-186.
25. Raynal N.J., Momparler L., Charbonneau M., Momparler R.L. Antileukemic activity of genistein, a major isoflavone present in soy products. J Nat Prod 2008, 71:3-7.
26. Raynal N.J., Charbonneau M., Momparler L.F., Momparler R.L. Synergistic effect of 5-aza-2′-deoxycytidine and genistein in combination against leukemia. Oncol Res 2008, 17:223-230.
27. Brockman R.W., Cheng Y.C., Schabel F.M., Montgomery J.A. Metabolism and chemotherapeutic activity of 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980, 40:3610-3615.
28. Lemaire M., Chabot G.G., Raynal N.J., Momparler L.F., Hurtubise A., Bernstein M.L., et al. Importance of dose-schedule of 5-aza-2′-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008, 8:128-138.
29. Momparler R.L., Gonzales F.A. Effect of intravenous infusion of 5-aza-2′-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res 1978, 38:2673-2678.
30. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
31. Kakihara T., Fukuda T., Tanaka A., Emura I., Kishi K., Asami K., et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma 1998, 31:405-409.
32. Stammler G., Zintl F., Sauerbrey A., Volm M. Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia. Anti-cancer Drugs 1997, 8:517-521.
33. Cashen A.F., Shah A.K., Todt L., Fisher N., Dipersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008, 61:759-766.
34. Lin K.T., Momparler R.L., Rivard G.E. Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography. Ther Drug Monit 1983, 5:491-496.
35. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
36. Rüter, Wijermans P.W., Lübbert M. Superiority of prolonged low-dose azanucleoside administration: results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006, 106:1744-1750.